## Keming Gao

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7721945/keming-gao-publications-by-year.pdf

Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91 2,372 5.6 A-index ext. citations avg, IF L-index

#	Paper	IF	Citations
88	Cingulum bundle connectivity in treatment-refractory compared to treatment-responsive patients with bipolar disorder and healthy controls: a tractography and surgical targeting analysis <i>Journal of Neurosurgery</i> , <b>2022</b> , 1-13	3.2	
87	Transcranial alternating current stimulation for treating depression: a randomized controlled trial <i>Brain</i> , <b>2022</b> , 145, 83-91	11.2	1
86	Protein Biomarkers in Monocytes and CD4 Lymphocytes for Predicting Lithium Treatment Response of Bipolar Disorder: a Feasibility Study with Tyramine-Based Signal-Amplified Flow Cytometry <i>Psychopharmacology Bulletin</i> , <b>2022</b> , 52, 8-35	0.9	O
85	Correction of depression-associated circadian rhythm abnormalities is associated with lithium response in bipolar disorder. <i>Bipolar Disorders</i> , <b>2021</b> ,	3.8	1
84	Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. <i>Bipolar Disorders</i> , <b>2021</b> ,	3.8	8
83	Efficacy and safety of electroconvulsive therapy plus medication versus medication alone in acute mania: A meta-analysis of randomized controlled trials. <i>Psychiatry Research</i> , <b>2021</b> , 302, 114019	9.9	2
82	The mechanisms of action of lithium in bipolar disorder <b>2021</b> , 357-364		
81	Depression, anxiety, and quality of life <b>2021</b> , 415-424		
80	Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome. <i>Journal of Psychiatric Research</i> , <b>2021</b> , 140, 205-213	5.2	1
79	The association between lithium use and neurocognitive performance in patients with bipolar disorder. <i>Neuropsychopharmacology</i> , <b>2020</b> , 45, 1743-1749	8.7	6
78	Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder: A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials. <i>Journal of Clinical Psychopharmacology</i> , <b>2020</b> , 40, 167-179	1.7	4
77	Safety and Tolerability of Both Arm Ischemic Conditioning in Patients With Major Depression: A Proof of Concept Study. <i>Frontiers in Psychiatry</i> , <b>2020</b> , 11, 570	5	O
76	Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder at Any Phase of Illness and at least Mild Symptom Severity. <i>Psychopharmacology Bulletin</i> , <b>2020</b> , 50, 8-25	0.9	2
75	The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study. <i>Journal of Affective Disorders</i> , <b>2020</b> , 266, 772-781	6.6	9
74	Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics?. <i>Journal of Affective Disorders</i> , <b>2020</b> , 261, 259-270	6.6	1
73	Clinical Evaluation of Cingulum Bundle Connectivity for Neurosurgical Hypothesis Development. <i>Neurosurgery</i> , <b>2020</b> , 86, 724-735	3.2	5
72	Connectivity-based identification of a potential neurosurgical target for mood disorders. <i>Journal of Psychiatric Research</i> , <b>2020</b> , 125, 113-120	5.2	6

## (2018-2019)

71	Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. Journal of Affective Disorders, <b>2019</b> , 259, 164-172	6.6	8
70	Comparison of common side effects from mood stabilizers and antipsychotics between pediatric and adult patients with bipolar disorder: a systematic review of randomized, double-blind, placebo-controlled trials. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 703-717	4.1	2
69	Perspective on Etiology and Treatment of Bipolar Disorders in China: Clinical Implications and Future Directions. <i>Neuroscience Bulletin</i> , <b>2019</b> , 35, 608-612	4.3	2
68	Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. Journal of Affective Disorders, 2019, 257, 17-22	6.6	10
67	Evolution in the Treatment of Psychiatric Disorders: From Psychosurgery to Psychopharmacology to Neuromodulation. <i>Frontiers in Neuroscience</i> , <b>2019</b> , 13, 108	5.1	24
66	Longitudinally Measured Changes in Somnolence Severity With a Visual Analog Scale in a Randomized Lithium Versus Quetiapine-IR Study in Bipolar Disorder. <i>Journal of Clinical</i> <i>Psychopharmacology</i> , <b>2019</b> , 39, 249-253	1.7	1
65	Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. <i>Journal of Affective Disorders</i> , <b>2019</b> , 246, 126-131	6.6	8
64	Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. <i>Journal of Affective Disorders</i> , <b>2019</b> , 245, 957-964	6.6	14
63	Can obesity in a major depressive episode be considered as a biomarker for bipolar spectrum disorders?. <i>Bipolar Disorders</i> , <b>2019</b> , 21, 11-12	3.8	1
62	Chronotype and cellular circadian rhythms predict the clinical response to lithium maintenance treatment in patients with bipolar disorder. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 620-628	8.7	43
61	Correlation between depression/anxiety symptom severity and quality of life in patients with major depressive disorder or bipolar disorder. <i>Journal of Affective Disorders</i> , <b>2019</b> , 244, 9-15	6.6	26
60	Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. <i>Bipolar Disorders</i> , <b>2019</b> , 21, 350-360	3.8	4
59	Bipolar disorders. <i>Nature Reviews Disease Primers</i> , <b>2018</b> , 4, 18008	51.1	289
58	Treatment outcomes of acute bipolar depressive episode with psychosis. <i>Depression and Anxiety</i> , <b>2018</b> , 35, 402-410	8.4	4
57	Nonconvulsive Status Epilepticus After Electroconvulsive Therapy: A Review of Literature. <i>Psychosomatics</i> , <b>2018</b> , 59, 36-46	2.6	5
56	Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial. <i>Journal of Affective Disorders</i> , <b>2018</b> , 225, 563-568	3 <sup>6.6</sup>	15
55	Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2018</b> , 52, 994-1002	2.6	2
54	A Pilot Study of the Effectiveness of Lithium Versus Quetiapine Immediate Release Monotherapy in Patients With Bipolar Spectrum Disorders. <i>Journal of Clinical Psychopharmacology</i> , <b>2018</b> , 38, 422-434	1.7	10

53	Depression severity and quality of life of qualified and unqualified patients with a mood disorder for a research study targeting anhedonia in a clinical sample. <i>Asian Journal of Psychiatry</i> , <b>2017</b> , 27, 40-4	17 <sup>6.7</sup>	6
52	A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use. <i>Psychopharmacology</i> , <b>2017</b> , 234, 2233-2244	4.7	8
51	Clinical correlates of acute bipolar depressive episode with psychosis. <i>Journal of Affective Disorders</i> , <b>2017</b> , 217, 29-33	6.6	11
50	Poor quality of life and functioning in bipolar disorder. <i>International Journal of Bipolar Disorders</i> , <b>2017</b> , 5, 10	5.4	34
49	Is there a Weight neutralVsecond-generation antipsychotic for bipolar disorder?. Expert Review of Neurotherapeutics, 2017, 17, 407-418	4.3	11
48	The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder. <i>Expert Opinion on Drug Discovery</i> , <b>2017</b> , 12, 1067-1081	6.2	4
47	Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. Journal of Affective Disorders, <b>2017</b> , 223, 146-152	6.6	12
46	Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. <i>CNS Spectrums</i> , <b>2016</b> , 21, 403-418	1.8	35
45	Subjective Versus Objective Weight Gain During Acute Treatment With Second-Generation Antipsychotics in Schizophrenia and Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , <b>2016</b> , 36, 637-642	1.7	17
44	Pharmacogenetics of lithium response: close to clinical practice?. <i>Lancet, The</i> , <b>2016</b> , 387, 1034-1036	40	3
43	A Randomized, Placebo-Controlled Pilot Study of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Current Generalized Anxiety Disorder. <i>Psychopharmacology Bulletin</i> , <b>2016</b> , 46, 8-23	0.9	10
42	Pharmacological Treatment of the Maintenance Phase of Bipolar Depression: Efficacy and Side Effects. <i>Milestones in Drug Therapy</i> , <b>2016</b> , 213-242		
41	Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management. <i>CNS Drugs</i> , <b>2016</b> , 30, 845-67	6.7	38
40	The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample. <i>BMC Psychiatry</i> , <b>2016</b> , 16, 129	4.2	42
39	Disagreement between self-reported and clinician-ascertained suicidal ideation and its correlation with depression and anxiety severity in patients with major depressive disorder or bipolar disorder. Journal of Psychiatric Research, 2015, 60, 117-24	5.2	23
38	Validation of the Chinese Version of the Short TEMPS-A and its application in patients with mood disorders. <i>Journal of Affective Disorders</i> , <b>2015</b> , 170, 178-84	6.6	4
37	Mood Stabilizers <b>2015</b> , 2129-2158		5
36	Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat. <i>Neuroscience Bulletin</i> , <b>2015</b> , 31, 572-88	4.3	15

## (2010-2015)

35	Corpus callosum atrophy associated with the degree of cognitive decline in patients with Alzheimer's dementia or mild cognitive impairment: a meta-analysis of the region of interest structural imaging studies. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 63, 10-9	5.2	15
34	Pharmacological Treatment Bipolar Depression <b>2015</b> , 281-298		2
33	MiRNA-206 and BDNF genes interacted in bipolar I disorder. <i>Journal of Affective Disorders</i> , <b>2014</b> , 162, 116-9	6.6	28
32	Association between brain-derived neurotrophic factor genetic polymorphism Val66Met and susceptibility to bipolar disorder: a meta-analysis. <i>BMC Psychiatry</i> , <b>2014</b> , 14, 366	4.2	17
31	The relationship between neurotrophins and bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , <b>2014</b> , 14, 51-65	4.3	17
30	Guidelines disconcordance in acute bipolar depression: data from the national Bipolar Mania Pathway Survey (BIPAS) in mainland China. <i>PLoS ONE</i> , <b>2014</b> , 9, e96096	3.7	9
29	Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, 1062-8	4.6	22
28	Should an assessment of Axis I comorbidity be included in the initial diagnostic assessment of mood disorders? Role of QIDS-16-SR total score in predicting number of Axis I comorbidity. <i>Journal of Affective Disorders</i> , <b>2013</b> , 148, 256-64	6.6	29
27	Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 425-31	1.7	10
26	Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. <i>Neuropsychiatric Disease and Treatment</i> , <b>2013</b> , 9, 1145-57	3.1	20
25	Decreased interhemispheric coordination in treatment-resistant depression: a resting-state fMRI study. <i>PLoS ONE</i> , <b>2013</b> , 8, e71368	3.7	51
24	Second-generation antipsychotics in major depressive disorder: update and clinical perspective. <i>Current Opinion in Psychiatry</i> , <b>2011</b> , 24, 10-7	4.9	53
23	Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2011</b> , 14, 131-42	5.8	17
22	Communication of potential benefits and harm to patients and payers in psychiatry: a review and commentary. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, B62-76	3.5	5
21	Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study. <i>Human Psychopharmacology</i> , <b>2011</b> , 26, 588-95	2.3	4
20	Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 1063-71	4.6	50
19	Independent predictors for lifetime and recent substance use disorders in patients with rapid-cycling bipolar disorder: focus on anxiety disorders. <i>American Journal on Addictions</i> , <b>2010</b> , 19, 440-	 <b>3</b> ·7	23
18	Comorbid anxiety and substance use disorders associated with a lower use of mood stabilisers in patients with rapid cycling bipolar disorder: a descriptive analysis of the cross-sectional data of 566 patients. <i>International Journal of Clinical Practice</i> , <b>2010</b> , 64, 336-44	2.9	16

17	Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. <i>Bipolar Disorders</i> , <b>2010</b> , 12, 404-13	3.8	127
16	Switching to hypomania and mania: differential neurochemical, neuropsychological, and pharmacologic triggers and their mechanisms. <i>Current Psychiatry Reports</i> , <b>2010</b> , 12, 512-21	9.1	15
15	Predictors of non-stabilization during the combination therapy of lithium and divalproex in rapid cycling bipolar disorder: a post-hoc analysis of two studies. <i>Psychopharmacology Bulletin</i> , <b>2010</b> , 43, 23-3	8 <sup>0.9</sup>	9
14	Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. <i>Psychopharmacology Bulletin</i> , <b>2010</b> , 43, 5-21	0.9	10
13	Medical and substance use comorbidity in bipolar disorder. <i>Journal of Affective Disorders</i> , <b>2009</b> , 116, 64-	<b>-9</b> 6.6	31
12	Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. <i>Expert Review of Neurotherapeutics</i> , <b>2009</b> , 9, 1147-58	4.3	31
11	A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence. <i>Journal of Clinical Psychiatry</i> , <b>2009</b> , 70, 113-21	4.6	71
10	Correlates of historical suicide attempt in rapid-cycling bipolar disorder: a cross-sectional assessment. <i>Journal of Clinical Psychiatry</i> , <b>2009</b> , 70, 1032-40	4.6	32
9	Pharmacological treatment of the maintenance phase of bipolar depression: focus on relapse prevention studies and the impact of design on generalizability <b>2009</b> , 159-178		3
8	Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. <i>Bipolar Disorders</i> , <b>2008</b> , 10, 907-15	3.8	32
7	Differential interactions between comorbid anxiety disorders and substance use disorder in rapid cycling bipolar I or II disorder. <i>Journal of Affective Disorders</i> , <b>2008</b> , 110, 167-73	6.6	24
6	Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. <i>Journal of Clinical Psychopharmacology</i> , <b>2008</b> , 28, 203-9	1.7	140
5	A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 302-9	4.6	56
4	Clinical correlates of patients with rapid-cycling bipolar disorder and a recent history of substance use disorder: a subtype comparison from baseline data of 2 randomized, placebo-controlled trials. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 1057-63	4.6	17
3	Acute treatment of mania: an update on new medications. Current Psychiatry Reports, 2006, 8, 504-9	9.1	21
2	Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 1327-40	4.6	112
1	Typical and atypical antipsychotics in bipolar depression. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 1376-8	54.6	43